NEW YORK (GenomeWeb) – Veracyte today released its preliminary third quarter financial results, projecting a 51 percent jump in revenues on higher sales and gains made with payors for its Afirma gene expression classifier thyroid test.

For the three-month period ended September 30, Veracyte said that its revenues are expected to be $18.6 million compared to $12.3 million in the same period last year, which would exceed analysts' consensus estimate of $15.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.